Have Patent License, Will Sue: Medtronic, Boston Sci Face Off In Supreme Court
This article was originally published in The Gray Sheet
Medtronic appeared to have the edge over Boston Scientific in Nov. 5 oral arguments over which side needs to prove its case when a patent licensee sues its licensor to get out of paying product royalties. The Supreme Court ruling has implications for which side has more leverage in licensing agreements, which are common in the device industry.
You may also be interested in...
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.